Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure

European Journal of Heart Failure

Volumn 13, Issue 9, 2011, Pages 968-973

  Balling, Louise ^a   Schou, Morten ^b   Videbæk, Lars ^c   Hildebrandt, Per ^d   Wiggers, Henrik ^e   Gustafsson, Finn ^a  

^a Rigshospitalet   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d FREDERIKSBERG HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Heart failure; Hyponatraemia; Outpatient

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; SPIRONOLACTONE;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OUTPATIENT; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REGISTER; RISK FACTOR; SODIUM BLOOD LEVEL; SURVIVAL;

AGED; COHORT STUDIES; DENMARK; FEMALE; HEART FAILURE; HUMANS; HYPONATREMIA; MALE; OUTPATIENTS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 80052005754     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr086     Document Type: Article

References (30)

1. Gerasimos Filippatos FD, Parissis J, Kremastinos DTH, Gheorghiade M. Hyponatremia in heart failure. Heart Fail Rev 2009;14:59-63.
2. Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol 2005;95(suppl): 2B-7B. (Pubitemid 40545926)
3. Ghali JK, Tam SW. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Card Fail 2010;16:419-431.
4. Bettari L, Fiuzat M, Felker GM, O'Connor CM. Significance of hyponatremia in heart failure. Heart Fail Rev 2010;doi:10.1007/s10741-010-9193-3. Published online ahead of print 14 September 2010.
5. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SP, Swedberg K, ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
6. Gustafsson F, Ulriksen H, Villadsen H, Nielsen H, Bach Andersen B, Hildebrandt R. Treatment with beta-blockers in nurse-led heart failure clinics: titration efficacy and predictors of failure. Eur J Heart Fail 2005;7:283-284.
7. Dewolfe A, Lopez B, Arcement LM, Hebert K. Low Serum Sodium as a Poor Prognostic Indicator for Mortality in Congestive Heart Failure Patients. Clin Cardiol 2010;33:E13-E17.
8. Gustafsson F, Schou M, Videbaek L, Nielsen T, Ulriksen H, Markenvard J, Svendsen TL, Ryde H, Vigholt E, Hildebrandt P, Danish Heart Failure Clinics Network. Treatment with beta-blockers in nurse-led heart failure clinics: titration efficacy and predictors of failure. Eur J Heart Fail 2007;9:910-916. (Pubitemid 47332310)
9. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003;56:124-130. (Pubitemid 36315938)
10. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342:1581-1589. (Pubitemid 30340505)
11. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF, Califf RM, Gheorghiade M, For the OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study. Circulation 2005;111:2454-2460. (Pubitemid 40696133)
12. Gheorghiade M, GattisWA, O'Connor CM, Adams KF, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C, For the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-1971. (Pubitemid 38544277)
13. Gheorghiade M, Abraham WT, Albert NM, Stough WG, Greenberg BH, O'Connor CM, She L, Yancy CW, Young J, Fonarow GC, OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28:980-988. (Pubitemid 47343897)
14. Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-1331. (Pubitemid 46513233)
15. Vazquez R, Bayes-Genis A, Cygankiewicz I, Pascual-Figal D, Grigorian-Shamagian L, Pavon R, Gonzalez-Juanatey JR, Cubero JM, Pastor L, Ordonez-Llanos L, Cinca J, Bayes de Luna A, MUSIC Investigators. The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 2009;30:1088-1096.
16. Kearney MT, Fox KAA, Lee AJ, Brooksby WP, Shah AM, Flapan A, Prescott RJ, Andrews R, Batin PD, Eckberg DL, Gall N, Zaman AG, Lindsay HS, Nolan J. Predicting sudden death in patients with mild to moderate chronic heart failure. Heart 2004;90:1137-1143. (Pubitemid 39279897)
17. Barsheshet A, Shotan A, Cohen E, Garty M, Goldenberg I, Sandach A, Behar S, Zimlichman E, Lewis B, Gottlieb S. Predictors of long-term (4-year) mortality in elderly and young patients with acute heart failure. Eur J Heart Fail 2010;12: 833-840.
18. Sica DA. Hyponatremia and heart failure-pathophysiology and implications. Congest Heart Fail 2005;11:274-277.
19. Lilly LS, Dzau VJ, Williams GH, Rydstedt L, Hollenberg NK. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J Clin Endocrinol Metab 1984;59:924-930. (Pubitemid 14020694)
20. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987;75:IV80-IV92.
21. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-266. (Pubitemid 11087371)
22. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983;1:1385-1390. (Pubitemid 13054124)
23. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010;122:265-272.
24. Packer M, Medina N, Yushak M. Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. J Am Coll Cardiol 1984;3:1035-1043. (Pubitemid 14171221)
25. Packer M, Lee WH, Kessler PD, Medina N, Yushak M, Gottlieb SS. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol 1987;10:837-844. (Pubitemid 17163109)
26. Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA, Maisch B, Hetzel M, Jaillon P, Boissel JP, Mallet A. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997;96:2197-2205. (Pubitemid 27425823)
27. Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol 1994;23:814-821. (Pubitemid 24074966)
28. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120: S1-S21. (Pubitemid 350027722)
29. Aronson D, Verbalis JG, Mueller M, Krum H. Short-and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Eur J Heart Fail 2011;13:326-336.
30. Konstam MA, Udelson JE. Hyponatraemia and vasopressin in heart failure: markers or mediators? Eur J Heart Fail 2011;13:242-244.